[The statement of Polish Gynecological Society Experts on the treatment of acute vulvovaginal candidiasis with prolonged releasing 2% butoconazole nitrate vaginal cream--state of art in 2008].
Vulvovaginal infection is the most common cause of gynecological problems in sexually active women. Knowledge about pharmacological properties of drugs used in treatment vulvovaginal candidiasis allows for tailoring therapy to each patient. 2% butoconazole nitrate vaginal cream is modern and up to date option for treatment of acute vulvovaginal candidiasis. Short- and long-term therapeutic efficacy of butoconazole vaginal cream was confirmed in numerous high reliability clinical trials. Good tolerance, high effectiveness of single therapeutic dose and high level of patient's acceptance gives the specialist powerful and efficient tool for management of VVC.
D000208:Acute Disease; D000287:Administration, Topical; D000935:Antifungal Agents / Q000627:therapeutic use*; D002175:Candida / Q000187:drug effects; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy* / Q000382:microbiology / Q000517:prevention & control; D002908:Chronic Disease; D003226:Congresses as Topic; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007318:Inservice Training / Q000592:standards; D009313:National Health Programs / Q000592:standards; D009824:Ointments; D011044:Poland; D011785:Quality Assurance, Health Care / Q000592:standards; D012008:Recurrence; D012955:Societies, Medical / Q000592:standards; D016387:Women's Health
D000935:Antifungal Agents; D007093:Imidazoles; D009824:Ointments; C017125:butoconazole